Mazdutide 5MG

Product details

Mazdutide

Product Name: Mazdutide (also known as IBI362, LY3305677)
Molecular Formula: C₂₁₀H₃₂₂N₄₆O₆₇
Molecular Weight: Not publicly disclosed (~large peptide/fusion construct)
Sequence: Synthetic linear peptide (33 amino acids) conjugated to a C20 fatty diacid via a hydrophilic linker—albumin-binding design enhances half-life.
Purity: ≥98% (HPLC Verified)
Form: Lyophilized powder
Packaging: Sterile vial; typical vial sizes include 1 mg or as specified
Storage: Store at −20 °C. Protect from light and moisture
Shelf Life: Stable for at least 12 months when stored at −20 °C

🔬 Product Overview:

Mazdutide is a novel dual agonist targeting both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), designed as an oxyntomodulin analog for therapeutic research into obesity and type 2 diabetes.

Its unique dual mechanism not only aids glycemic control through GLP-1R activation (enhancing insulin secretion and satiety) but also improves metabolic regulation by activating GCGR—boosting energy expenditure, reducing liver fat, and enhancing lipid metabolism.

High Purity Research Peptide 

Technical Specifications

Product Description

Mazdutide is a meticulously engineered synthetic peptide with an albumin-binding fatty diacid moiety that confers a sustained pharmacokinetic profile. As the first approved dual GLP-1/GCGR receptor agonist (approved in China in June 2025) , it represents a next-generation approach in metabolic therapeutics.

Clinical evidence demonstrates robust efficacy in weight reduction and cardiometabolic improvements:

• In the GLORY-1 Phase III study (48 weeks), reductions in body weight reached approximately 12.0% (4 mg dose) and 14.8% (6 mg dose); >50% of participants achieved ≥15% weight loss, outperforming placebo (~0.5%) .
• Waist circumference decreased by about 9–11 cm, with significant reductions in liver fat content (up to ~80%).
• DREAMS-1 trial in type 2 diabetes showed meaningful HbA1c reductions (−1.57% at 4 mg, −2.15% at 6 mg), with the majority reaching <7% target glycemic control; robust weight loss and metabolic benefits also observed.
• Across trials, Mazdutide was well tolerated, with primarily mild to moderate gastrointestinal symptoms and no new safety signals.

Mazdutide offers a dual-targeted, once-weekly peptide platform for researchers exploring integrated approaches to obesity, diabetes, fatty liver disease, and broader metabolic dysfunction.

Precautions:

For research purposes only. Not approved for human or veterinary use. Handle under appropriate laboratory conditions and safety protocols.